Skip to main content
SpringerLink
Log in
Book cover

Neuropeptide Y and Related Peptides pp 505–546Cite as

Structure-Activity Relationships of Nonpeptide Neuropeptide Y Receptor Antagonists

  • Chapter

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 162))

Abstract

Reports in 1990 on some weakly to moderately active nonpeptides which were not originally designed for neuropeptide Y (NPY) receptors, followed by the discovery of the first highly potent and selective Y1 receptor antagonists— the (R)-argininamide BIBP 3226 and the benzamidine derivative SR 120819A—as well as raising hope for novel drug treatment of hypertension, obesity and metabolic diseases stimulated the search for NPY-blocking compounds. Most of the currently known nonpeptidic NPY antagonists are ligands of Y1 or Y5 receptors, whereas only one class of Y2 selective antagonists around the (S)-arginine derivative BIIE 0246 has been disclosed. Nonpeptidic ligands of the Y Y4 receptor are not known. In some cases the design of Y1 antagonists followed rational strategies considering amino acids which are essential for binding to Y1 and/or Y2 receptors according to results of a complete alanine scan of NPY. Typical Y1 antagonists (e.g., compounds of the argininamide, benzamidine, benzimidazole, indole and aminopyridine series) have one or two basic groups which—according to the working hypothesis—could mimic Arg33 and/ or Arg35 in NPY. Binding models derived for some compounds (e.g., BIBP 3226 and J-104870) based on investigations with Y1 receptor mutants suggest key interactions between the basic group(s) and acidic residues of the Y1 receptor protein, especially Asp287. Compared to Y1 antagonists the known Y5 antagonists are often based on hits from screening of libraries and show a considerably higher degree of structural diversity. Nevertheless many highly active Y5 antagonists represent a common structural pattern suggesting at least overlapping binding sites.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abounader R, Villemure JG, Hamel E (1995) Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226. Br J Pharmacol 116:2245–2250

    PubMed  CAS  Google Scholar 

  • Aiglstorfer I, Uffrecht A, Gessele K et al. (1998) NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures. Regul Pept 75/76:9–21

    Google Scholar 

  • Aiglstorfer I, Hendrich I, Moser C et al. (2000) Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226. Bioorg Med Chem Lett 10:1597–1600

    PubMed  CAS  Google Scholar 

  • Akwabi-Ameyaw A, Heyer D, Aquino C et al. (2001) Synthesis and SAR of substituted 5-acylamino benzimidazoles as potent neuropeptide Y Y5 antagonists. 222nd ACS National Meeting. Chicago, August 2001 (abstract MEDI-033)

    Google Scholar 

  • Allen J, Novotny J, Martin J et al. (1987) Molecular structure of mammalian neuropeptide Y: analysis by molecular cloning and computer-aided comparison with crystal structure of avian homologue. Proc Natl Acad Sci USA 84:2532–2536

    PubMed  CAS  Google Scholar 

  • Antonsson T, Bergman N-A, Linschoten M et al., AstraZeneca (2001) Preparation and effect of diphenylacetylaminoalkylamides as neuropeptide Y antagonists. Patent WO 2001002364

    Google Scholar 

  • Aoki K, Nishikawa N, Ikekawa A et al., Meiji Seika Kaisha, Japan (2001) Preparation of benzothiazolone derivatives having affinity to neuropeptide Y receptor. Patent Jp 2001122865

    Google Scholar 

  • Beck-Sickinger AG, Wieland HA, Wittneben H et al. (1994) Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations. Eur J Biochem 225:947–958

    PubMed  CAS  Google Scholar 

  • Beck-Sickinger AG (1997) The importance of various parts of the NPY molecule for receptor recognition. In: Grundemar L, Bloom SR (eds) Neuropeptide Y and drug development. Academic Press, London, San Diego, pp 107–126

    Google Scholar 

  • Bell D, McDermott BJ (1998) D-myo inositol 1,2,6, trisphosphate (α-trinositol, pp56): selective antagonist at neuropeptide Y (NPY) Y-receptors or selective inhibitor of phosphatidylinositol cell signaling? Gen Pharmacol 31:689–696

    PubMed  CAS  Google Scholar 

  • Benfey BG (1982) Two long acting alpha-adrenoceptor blocking drugs: benextramine and phenoxybenzamide. Trends Pharmacol Sci 8:231

    Google Scholar 

  • Berglund MM, Fredriksson R, Salaneck E et al. (2002) Reciprocal mutations of neuropeptide Y receptor Y2 in human and chicken identify amino acids important for antagonist binding. FEBS Lett 518:5–9

    PubMed  CAS  Google Scholar 

  • Block MH, Donald CS, Foote KM et al, AstraZeneca UK Ltd (2001) Preparation of carbazoles as neuropeptide Y5 receptor ligand. Patent WO 0107409

    Google Scholar 

  • Block MH, Boyer S, Brailsford W et al. (2002) Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity. J Med Chem 45:3509–3523

    PubMed  CAS  Google Scholar 

  • Blum CA, Desimone R, Hutchison A et al., Neurogen Corp., USA (2000) Certain amidoand amino-substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands. Patent US 6133265

    Google Scholar 

  • Britton TC, Spinazze PG, Hipskind PA et al. (1999) Structure-activity relationships of a series of benzothiophene-derived NPY Y1 antagonists: optimization of the C-2 side chain. Bioorg Med Chem Lett 9:475–480

    PubMed  CAS  Google Scholar 

  • Buschauer A (1989) Synthesis and in vitro pharmacology of arpromidine and related phenyl( pyridylalkyl)guanidines, a potential new class of positive inotropic drugs. J Med Chem 32:1963–1970

    PubMed  CAS  Google Scholar 

  • Carpino PA, Hammond M, Hank RF, Pfizer Products Inc., USA (2000) Amide derivatives useful as Neuropeptide Y (NPY) antagonists. Patent EP 1033366

    Google Scholar 

  • Carpino PA (2000) Patent focus on new anti-obesity agents: September 1999–February 2000. Expert Opin Ther Pat 10:819–831

    CAS  Google Scholar 

  • Chaurasia C, Misse G, Tessel R et al. (1994) Nonpeptide peptidomimetic antagonists of the neuropeptide Y receptor: benextramine analogs with selectivity for the peripheral Y2 receptor. J Med Chem 37:2242–2248

    PubMed  CAS  Google Scholar 

  • Connell RD, Lease TG, Ladouceur GH et al., Bayer Corp., USA (2000) Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists. Patent US 6048900

    Google Scholar 

  • Criscione L, Yamaguchi Y, Mah R et al., Novartis AG, Switzerland (1997) Receptor Antagonists. Patent WO 9720823

    Google Scholar 

  • Criscione L, Rigollier P, Batzl-Hartmann C et al. (1998) Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J Clin Invest 102:2136–2145

    PubMed  CAS  Google Scholar 

  • Daniels AJ, Chance WT, Grizzle MK et al. (2001) Food intake inhibition and reduction in body weight gain in rats treated with GI264879A, a non-selective NPY-Y1 receptor antagonist. Peptides 22:483–491

    PubMed  CAS  Google Scholar 

  • Daniels AJ, Grizzle MK, Wiard RP et al. (2002) Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist. Regul Pept 106:47–54

    PubMed  CAS  Google Scholar 

  • Dax SL, Lovenberg TW, Baxter EW et al., Ortho-McNeil (2000) N-Aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor. Patent WO 0020376

    Google Scholar 

  • Dax SL, McNally JJ, Ortho-McNeil (2000) 3a,4,5,9b-tetrahydro-lH-benz[e]indol-2-yl amine-derived neuropeptide Y receptor ligands useful in the treatment of obesity and other disorders. Patent WO 0068197

    Google Scholar 

  • Dax SL, McNally JJ, Youngman MA, Ortho-McNeil (2001) Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders. Patent WO 0109120

    Google Scholar 

  • Dax SL (2002) Small-molecule neuropeptide Y Y5 antagonists. Drugs Fut 27:273–287

    CAS  Google Scholar 

  • Delia Zuana O, Sadlo M, Germain M et al. (2001) Reduced food intake in response to CGP 71683A may be due to mechanisms other than NPY Y5 receptor blockade. Int J Obes Relat Metab Disord 25:84–94

    Google Scholar 

  • Dollinger H, Esser F, Mihm G et al., Boehringer Ingelheim Pharma K.-G., Germany (1999) Preparation of novel peptides for use as NPY antagonists. Patent DE 19816929

    Google Scholar 

  • Donald CS, Foote KM, Schofield P et al., AstraZeneca, UK (2002) Carbazole derivatives and their use as neuropeptide Y5 receptor ligands. Patent WO 02051806

    Google Scholar 

  • Doods H, Gaida W, Wieland HA et al. (1999) BIIE0246: A selective and high affinity neuropeptide Y Y2 receptor antagonist. Eur J Pharmacol 384:R3–R5

    PubMed  CAS  Google Scholar 

  • Doods HN, Wienen W, Entzeroth M et al. (1995) Pharmacological characterization of the selective nonpeptide neuropeptide Y1 receptor antagonist BIBP 3226. J Pharmacol ExpTher 275:136–142

    CAS  Google Scholar 

  • Doods HN, Wieland HA, Engel W et al. (1996) BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: a review of its pharmacological properties. Regul Pept 65:71–77

    PubMed  CAS  Google Scholar 

  • Doughty MB, Chu SS, Miller DW et al. (1990) Benextramine: a long-lasting neuropeptide Y receptor antagonist. Eur J Pharmacol 185:113–114

    PubMed  CAS  Google Scholar 

  • Doughty MB, Li K, Hu L et al. (1992) Benextramine-neuropeptide Y (NPY) binding site interactions: characterization of 3H-NPY binding site heterogeneity in rat brain. Neuropeptides (Edinburgh) 23:169–180

    CAS  Google Scholar 

  • Doughty MB, Chaurasia CS, Li K (1993) Benextramine-neuropeptide Y receptor interactions: contribution of the benzylic moieties to [3H]neuropeptide Y displacement activity. J Med Chem 36:272–279

    PubMed  CAS  Google Scholar 

  • Dove S, Michel MC, Knieps S et al. (2000) Pharmacology and quantitative structure-activity relationships of imidazolylpropylguanidines with mepyramine-like substructures as non-peptide neuropeptide Y Y1 receptor antagonists. Can J Physiol Pharmacol 78:108–115

    PubMed  CAS  Google Scholar 

  • Dow RL, Hammond M, Pfizer Products Inc., USA (2001) 4-aminopyrrolo[3,2-d]pyrimidines as neuropeptide Y receptor antagonists. Patent US 6187778

    Google Scholar 

  • Du P, Salon JA, Tamm JA et al. (1997a) Modeling the G-protein-coupled neuropeptide Y Y1 receptor agonist and antagonist binding sites. Protein Eng 10:109–117

    PubMed  CAS  Google Scholar 

  • Du P, Finn JM, Jeon YT et al., Synaptic Pharmaceutical Corp. (1997b) Aryl sulfonamide and sulfamide derivatives and uses thereof. Patent WO 9719682

    Google Scholar 

  • Duhault J, Boulanger M, Chamorro S et al. (2000) Food intake regulation in rodents: Y5 or Y1 NPY receptors or both? Can J Physiol Pharmacol 78:173–185

    PubMed  CAS  Google Scholar 

  • Dumont Y, Cadieux A, Doods H et al. (2000a) BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y2 receptor antagonist. Br J Pharmacol 129:1075–1088

    PubMed  CAS  Google Scholar 

  • Dumont Y, Cadieux A, Doods H et al. (2000b) Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIBO3304 (Y1) and CGP71683A (Y5). Can J Physiol Pharmacol 78:116–125

    PubMed  CAS  Google Scholar 

  • Edvinsson L, Adamsson M, Jansen I (1990) Neuropeptide Y antagonistic properties of D-myo-inositol-1.2.6-trisphosphate in guinea pig basilar arteries. Neuropeptides 17:99–105

    PubMed  CAS  Google Scholar 

  • Elliott RL, Hammond M, Hank RF, Pfizer Products Inc. (2000) 2-Pyridyl-4-heteroarylimidazoles for the treatment of obesity. Patent WO 0066578

    Google Scholar 

  • Elliott RL, Oliver RM, Hammond M et al. (2003) In vitro and in vivo characterization of 3-[2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-lH-imidazol-4-yl]benzonitrile hydrochloride salt, a potent and selective NP Y5 receptor antagonist. J Med Chem 46:670–673

    PubMed  CAS  Google Scholar 

  • Esser F, Schnorrenberg G, Dollinger H et al., Boehringer Ingelheim Pharma K.-G., Germany (1999) Preparation of novel peptides for use as NPY antagonists. Patent DE 19816932

    Google Scholar 

  • Fang J, Aquino C, Heyer D et al. (2001) 2-Aminobenzimidazoles as neuropeptide Y Y5 antagonists: Solution phase synthesis and structure-activity relationships. 222nd ACS National Meeting. Chicago, August 2001 (abstractMEDI-026)

    Google Scholar 

  • Fauchere J-L, Ortuno J-C, Duhault J et al., Adir et Compagnie, France (2000) Aminotriazole compounds useful as neuropeptide Y receptor ligands, process for their preparation, and pharmaceutical compositions containing them. Patent EP 1044970

    Google Scholar 

  • Feletou M, Rodriguez M, Beauverger P et al. (1998) NPY receptor subtypes involved in the contraction of the proximal colon of the rat. Regul Pept 75/76:221-229

    Google Scholar 

  • Feletou M, Nicolas JP, Rodriguez M et al. (1999) NPY receptor subtype in the rabbit isolated ileum. Br J Pharmacol 127:795–801

    PubMed  CAS  Google Scholar 

  • Feth F, Erdbrugger W, Rascher W et al. (1993) Is PP56 (D-myo-inositol-l,2,6-trisphosphate) an antagonist at neuropeptide Y receptors? Life Sci 52:1835–1844

    PubMed  CAS  Google Scholar 

  • Fotsch C, Sonnenberg JD, Chen N et al. (2001) Synthesis and structure-activity relationships of trisubstituted phenyl urea derivatives as neuropeptide Y5 receptor antagonists. J Med Chem 44:2344–2356

    PubMed  CAS  Google Scholar 

  • Fritz JE, Kaldor SW, Scott WL et al, Eli Lilly & Co. (1998) 3-Arylpropylamino Neuropeptide Y Receptor Antagonists. Patent WO 9852890

    Google Scholar 

  • Fukami T, Fukuroda T, Kanatani A et al., Banyu Pharm. (1998a) Preparation of urea moiety-containing pyrazole derivatives as neuropeptide Y antagonists. Patent WO 9824768

    Google Scholar 

  • Fukami T, Fukuroda T, Kanatani A et al., Banyu Pharm. (1998b) Preparation of pyrazole derivatives for treatment of bulimia, obesity, and diabetes. Patent WO 9825907

    Google Scholar 

  • Fukami T, Fukuroda T, Kanatani A et al., Banyu Pharm. (1998c) Preparation of aminopyrazole derivatives for the treatment of bulimia, obesity, and diabetes. Patent WO 9827063

    Google Scholar 

  • Fukami T, Fukuroda T, Kanatani A et al., Banyu Pharm. (1998d) Preparation of novel aminopyrazole derivatives as neuropeptide Y antagonists. Patent WO 9825908

    Google Scholar 

  • Fukami T, Okamoto O, Fukuroda T et al., Banyu Pharm. (1998e) Preparation and formulation of aminopyridine derivatives as neuropeptide Y receptor antagonists. Patent WO 9840356

    Google Scholar 

  • Fukami T, Kanatani A, Ishihara A et al. (2001a) Synthesis and pharmacology of potent and selective aminopyridine NPY Y1 receptor antagonists. 222nd ACS National Meeting. Chicago, August 2001 (abstract MEDI-282)

    Google Scholar 

  • Fukami T, Kanatani A, Ishihara A et al., Banyu Pharm. (2001b) Preparation of spiroisoindolinepiperidines, spiroisoquinolinepiperidines, spiroisobenzofuranpiperidines and related compounds. Patent WO 0114376

    Google Scholar 

  • Fukuroda T, Kanatani A, Fukami T et al., Banyu Pharmaceutical Co. Ltd. (2001) Novel neuropeptide Y receptor antagonists. Patent WO 9915516

    Google Scholar 

  • Gao Y, McNeil D, Yang L et al., Merck; Banyu Pharm. (2000) Preparation of spiroindolines as Y5 receptor antagonists. Patent WO 0027845

    Google Scholar 

  • Gerald C, Walker MW, Criscione L et al. (1996) A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382:168–171

    PubMed  CAS  Google Scholar 

  • Gerald C, Weinschank RL, Walker MW et al, Synaptic Pharma Corp. (USA) (1997) DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof. Patent WO 9616542

    Google Scholar 

  • Grouzmann E, Buclin T, Martire M et al. (1997) Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. Synthesis and pharmacological evaluation of a Y2 antagonist. J Biol Chem 272:7699–7706

    PubMed  CAS  Google Scholar 

  • Grundemar L, Bloom SR (eds) (1997) Neuropeptide Y and drug development. London, San Diego, Academic Press

    Google Scholar 

  • Hammond M (2001) Neuropeptide Y receptor antagonists. IDrugs 4:920–927

    PubMed  CAS  Google Scholar 

  • Heilig M, Edvinsson L, Wahlestedt C (1991) Effects of intracerebroventricular D-myoinositol-l,2,6-trisphosphate (PP56), a proposed neuropeptide Y (NPY) antagonist, on locomotor activity, food intake, central effects of NPY and NPY-receptor binding. Eur J Pharmacol 209:27–32

    PubMed  CAS  Google Scholar 

  • Heyer D, Marron B, Miyasaki Y et al. (2001a) Discovery of a novel series of benzimidazole-based neuropeptide Y Y5 antagonists from a 7-TM targeted chemical library. 222nd ACS National Meeting, Chicago, August 2001 (abstract MEDI-030)

    Google Scholar 

  • Heyer D, Akwabi-Ameyaw A, Aquino C (2001b) Aminobenzimidazoles: A class of orally bioavailable and brain permeable neuropeptide Y Y5 antagonists. 222nd ACS National Meeting, Chicago, August 2001: (abstract MEDI-284)

    Google Scholar 

  • Hipskind PA, Lobb KL, Nixon JA et al. (1997) Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists. J Med Chem 40:3712–3714

    PubMed  CAS  Google Scholar 

  • Hutzler C (2001) Synthesis and pharmacological activity of new neuropeptide Y receptor ligands: from N,N-disubstituted alkanamides to highly potent argininamide-type Y1 antagonists. Doctoral thesis, University of Regensburg, Regensburg, Germany

    Google Scholar 

  • Hutzler C, Kracht J, Mayer M et al. (2001) NG-Acylated argininamides: highly potent selective NPY Y1 receptor antagonists with special properties, Arch. Pharm. Pharm. Med. Chem. 334,Suppl. 2, 17 (2001)

    Google Scholar 

  • Islam I, Dhanoa D, Finn J et al. (2002) Discovery of potent and selective small molecule NPY Y5 receptor antagonists. Bioorg Med Chem Lett 12:1767–1769

    PubMed  CAS  Google Scholar 

  • Itani H, Ito H, Sakata Y et al. (2002a) Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3:7-methoxy-l-hydroxy-1-substituted tetraline derivatives. Bioorg Med Chem Lett 12:799–802

    PubMed  CAS  Google Scholar 

  • Itani H, Ito H, Sakata Y et al. (2002b) Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 2: substituted benzo[a]cycloheptene derivatives. Bioorg Med Chem Lett 12:757–761

    PubMed  CAS  Google Scholar 

  • Iyengar S, Li DL, Simmons RM (1999) Characterization of neuropeptide Y-induced feeding in mice: do Y1–Y6 receptor subtypes mediate feeding? J Pharmacol Exp Ther 289:1031–1040

    PubMed  CAS  Google Scholar 

  • Jacques D, Cadieux A, Dumont Y et al. (1995) Apparent affinity and potency of BIBP3226, a non-peptide neuropeptide Y receptor antagonist, on purported neuropeptide Y Y1, Y2 and Y3 receptors. Eur J Pharmacol 278:R3–5

    PubMed  CAS  Google Scholar 

  • Kanatani A, Kanno T, Ishihara A et al. (1999) The novel neuropeptide Y Y1 receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem Biophys Res Commun 266:88–91

    PubMed  CAS  Google Scholar 

  • Kanatani A, Ishihara A, Iwaasa H et al. (2000a) L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem Biophys Res Commun 272:169–173

    PubMed  CAS  Google Scholar 

  • Kanatani A, Mashiko S, Murai N et al. (2000b) Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 141:1011–1016

    PubMed  CAS  Google Scholar 

  • Kanatani A, Hata M, Mashiko S et al. (2001) A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol Pharmacol 59:501–505

    PubMed  CAS  Google Scholar 

  • Kanno T, Kanatani A, Keen SLC et al. (2001) Different binding sites for the neuropeptide Y Y1 antagonists 1229U91 and J-104870 on human Y1 receptors. Peptides 22:405–413

    Google Scholar 

  • Kask A, Rago L, Harro J (1998) Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226. Br J Pharmacol 124:1507–1515

    PubMed  CAS  Google Scholar 

  • Kask A, Harro J (2000) Inhibition of amphetamine-and apomorphine-induced behavioural effects by neuropeptide Y Y(1) receptor antagonist BIBO 3304. Neuropharmacology 39:1292–1302

    PubMed  CAS  Google Scholar 

  • Kask A, Vasar E, Heidmets LT et al. (2001) Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat. Eur J Pharmacol 414:215–224

    PubMed  CAS  Google Scholar 

  • Kawanishi Y, Takenaka H, Hanasaki K et al., Shionogi + Co., Ltd, Japan (2001) Preparation of sulfonamides and sulfinamides as NPY Y5 antagonists. Patent WO 0137826

    Google Scholar 

  • Kirkpatrick P (2002) Dead end for NPY Y5-receptor antagonists? Nature Rev Drug Discov 1:932–933

    CAS  Google Scholar 

  • Knieps S, Dove S, Michel MC et al. (1996) ω-Phenyl-ω-(2-pyridyl)alkyl-substituted bisguanidines are moderate neuropeptide Y antagonists. Pharm Pharmacol Lett 6:27–30

    CAS  Google Scholar 

  • Kordik CP, Lovenberg TW, Reitz A, Ortho-McNeil Pharm. (2000) Preparation of pyrazole carboxamides for the treatment of obesity and other disorders. Patent WO 0069849

    Google Scholar 

  • Kordik CP, Luo C, Zanoni BC et al. (2001) Aminopyrazoles with high affinity for the human neuropeptide Y5 receptor. Bioorg Med Chem Lett 11:2283–2286

    PubMed  CAS  Google Scholar 

  • Lecklin A, Lundell I, Paananen L et al. (2002) Receptor subtypes Y1 and Y5 mediate neuropeptide Y induced feeding in the guinea-pig. Br J Pharmacol 135:2029–2037

    PubMed  CAS  Google Scholar 

  • Ling AL (1999) Neuropeptide Y receptor antagonists. Expert Opin Ther Pat 9:375–384

    CAS  Google Scholar 

  • Linn J, Aquino C, Dezube M (2001) Benzimidazole neuropeptide Y Y5 antagonists: rapid SAR development using a solid phase approach. 222nd ACS National Meeting. Chicago, August 2001: (abstract MEDI-027)

    Google Scholar 

  • Malmström RE, Balmer KC, Lundberg JM (1997) The neuropeptide Y (NPY) Y1 receptor antagonist BIBP 3226: equal effects on vascular responses to exogenous and endogenous NPY in the pig in vivo. Br J Pharmacol 121:595–603

    PubMed  Google Scholar 

  • Malmström RE, Alexandersson A, Balmer KC et al. (2000) In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22. J Cardiovasc Pharmacol 36:516–525

    PubMed  Google Scholar 

  • Malmström RE (2000) Neuropeptide Y Y1 receptor mediated mesenteric vasoconstriction in the pig in vivo. Regul Pept 95:59–63

    PubMed  Google Scholar 

  • Malmström RE (2001a) Vascular pharmacology of BIIE0246, the first selective non-peptide neuropeptide Y Y2 receptor antagonist, in vivo. Br J Pharmacol 133:1073–1080

    PubMed  Google Scholar 

  • Malmström RE, Balmer KC, Weilitz J et al. (2001) Pharmacology of H 394/84, a dihydropyridine neuropeptide Y Y(1) receptor antagonist, in vivo. Eur J Pharmacol 418:95–104.

    PubMed  Google Scholar 

  • Malmström RE (2001b) Existence of both neuropeptide Y, Y1 and Y2 receptors in pig spleen: evidence using subtype-selective antagonists in vivo. Life Sci 69:1999–2005

    PubMed  Google Scholar 

  • Malmström RE, Lundberg JN, Weitzberg E (2002a) Effects of the neuropeptide Y Y2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo. Naunyn Schmiedebergs Arch Pharmacol 365:106–111

    PubMed  Google Scholar 

  • Malmström RE, Lundberg JO, Weitzberg E (2002b) Autoinhibitory function of the sympathetic prejunctional neuropeptide Y Y(2) receptor evidenced by BIIE0246. Eur J Pharmacol 439:113–119

    PubMed  Google Scholar 

  • Malmström RE (2002) Pharmacology of neuropeptide Y receptor antagonists. Focus on cardiovascular functions. Eur J Pharmacol 447:11–30

    PubMed  Google Scholar 

  • Marzabadi MR, Wong WC, Noble SA, Synaptic Pharm. Corp., USA (2000a) Preparation of benzo[2,3]thiepino[4,5-d]thiazol-2-ylaminoalkylsulfonamides and related compounds as selective neuropeptide Y (Y5) antagonists. Patent US 6124331

    Google Scholar 

  • Marzabadi MR, Wong WC, Noble SA et al, Synaptic Pharm. Corp., USA. (2000b) Preparation of triazineamines, thiazolamines, and benzo[2,3]thiepino[4,5-d][l,3]thiazol-2-ylamines as selective NPY (Y5) antagonists. Patent WO 0064880

    Google Scholar 

  • Marzabadi MR, Wong WC, Noble SA et al., Synaptic Pharm. Corp., USA; Novartis A.-G. (2001) Preparation of selective NPY (Y5) antagonists and pharmaceutical compositions thereof for treating an abnormality modulated by human Y5 receptor activity. Patent WO 0102379

    Google Scholar 

  • McCombie S, Stamford AW, Huang Y et al., Schering-Plough Corp., USA (2002) Substituted urea neuropeptide Y Y5 receptor antagonists. Patent US 2002165223

    Google Scholar 

  • McNally J J, Youngman MA, Lovenberg TW et al. (2000a) N-acylated alpha-(3-pyridylmethyl)-beta-aminotetralin antagonists of the human neuropeptide Y Y5 receptor. Bioorg Med Chem Lett 10:1641–1643

    PubMed  CAS  Google Scholar 

  • McNally JJ, Youngman MA, Lovenberg TW et al. (2000b) N-(sulfonamido)alkyl[tetrahydro-1H-benzo[e]indol-2-yl]amines: potent antagonists of human neuropeptide Y Y5 receptor. Bioorg Med Chem Lett 10:213–216

    PubMed  CAS  Google Scholar 

  • Meister A (1999) Pharmacological characterization of new histamine and neuropeptide Y receptor ligands: set-up and validation of functional test models on isolated organs. Doctoral thesis, University of Regensburg, Regensburg, Germany

    Google Scholar 

  • Michel MC, Motulsky HJ (1990) He 90481: A compeptitive nonpeptidergic antagonist at neuropeptide Y receptors. Ann N Y Acad Sci 611:392–394

    Google Scholar 

  • Michel MC, Moersdorf JP, Engler H et al., Heumann Pharma G.m.b.H. und Co., Germany (1991) Use of guanidine derivatives for the manufacture of a medicament with neuropeptide Y-antagonistic activity. Patent EP448765

    Google Scholar 

  • Michel MC, Dove S, Buschauer A (1993) Arpromidine and related histamine H2 agonists as chemical leads for the development of non-peptide neuropeptide Y antagonists. Arch Pharm (Weinheim) 326:664

    Google Scholar 

  • Michel MC, Beck-Sickinger AG, Cox H et al. (1998) XVI. International Union of Pharmacology Recommandations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors. Pharmacological Reviews 50:143–150

    PubMed  CAS  Google Scholar 

  • Mollereau C, Gouarderes C, Dumont Y et al. (2001) Agonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226. Br J Pharmacol 133:1–4

    PubMed  CAS  Google Scholar 

  • Mollereau C, Mazarguil H, Marcus D et al. (2002) Pharmacological characterization of human NPFF(l) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists. Eur J Pharmacol 451:245–256

    PubMed  CAS  Google Scholar 

  • Morgan DGA, Small CJ, Abusnana S et al. (1998) The NPY Y1 receptor antagonist BIBP 3226 blocks NPY induced feeding via a non-specific mechanism. Regul Pept 75/76:377–382

    Google Scholar 

  • Moser C, Bernhardt G, Michel J et al. (2000) Cloning and functional expression of the hNPY Y5 receptor in human endometrial cancer (HEC-1B) cells. Can J Physiol Pharmacol 78:134–142

    PubMed  CAS  Google Scholar 

  • Müller M, Knieps S, Gessele K et al. (1997) Synthesis and neuropeptide Y Y1 receptor antagonistic activity of N,N-disubstituted ω-guanidino-and ω-aminoalkanoic acid amides. Arch Pharm (Weinheim) 330:333–342

    Google Scholar 

  • Murakami Y, Hagishita S, Okada T et al. (1999a) 1,3-disubstituted benzazepines as neuropeptide Y Y1receptor antagonists. Bioorg Med Chem 7:1703–1714

    PubMed  CAS  Google Scholar 

  • Murakami Y, Hara H, Okada T et al. (1999b) 1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists. J Med Chem 42:2621–2632

    PubMed  CAS  Google Scholar 

  • Nishikawa N, Aoki K, Suzuki M et al., Meiji Seika Kaisha Ltd., Japan (2000) Tricyclic compounds. Patent WO 0063171

    Google Scholar 

  • Norman MH, Chen N, Han N et al., Amgen Inc., USA (1999) Preparation of bicyclic pyridine and pyrimidine derivatives as neuropeptide Y receptor antagonists. Patent WO 9940091

    Google Scholar 

  • Norman MH, Chen N, Chen Z et al. (2000) Structure-Activity Relationships of a Series of Pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists. J Med Chem 43:4288–4312

    PubMed  CAS  Google Scholar 

  • Palczewski K, Kumasaka T, Hori T et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289:739–745

    PubMed  CAS  Google Scholar 

  • Palea S, Corsi M, Rimland JM et al. (1995) Discrimination by benextramine between the NPY-Y1 receptor subtypes present in rabbit isolated vas deferens and saphenous vein. Br J Pharmacol 115:3–10

    PubMed  CAS  Google Scholar 

  • Parker E, Van Heek M, Stamford A (2002) Neuropeptide Y receptors as targets for antiobesity drug development: perspective and current status. Eur J Pharmacol 440:173–187

    PubMed  CAS  Google Scholar 

  • Peterson JM, Blum CA, Cai G et al., Pfizer Inc., USA (1996) Certain substituted benzylamine derivatives: a new class of neuropeptide Y1 specific ligands. Patent WO 9640660

    Google Scholar 

  • Pheng LH, Quirion R, Iyengar S et al. (1997) The rabbit ileum: a sensitive and selective preparation for the neuropeptide Y Y5 receptor. Eur J Pharmacol 333:R3–5

    PubMed  CAS  Google Scholar 

  • Poindexter GS, Bruce M, Johnson G et al, Bristol-Myers Squibb Company, USA (1996) Dihydropyridine NPY antagonists: piperazine derivatives. Patent EP 747356

    Google Scholar 

  • Poindexter GS, Gillman K, Bristol-Myers Squibb Company, USA (1999a) Imidazolone anorectic agents: III. heteroaryl derivatives. Patent WO 9948873

    Google Scholar 

  • Poindexter GS, Gillman K, Bristol Myers Squibb Co., USA (1999b) Imidazolone anorectic agents: I. acyclic derivatives. Patent WO 9948888

    Google Scholar 

  • Poindexter GS, Antal I, Guipponi LM et al., Bristol-Myers Squibb Co. (1999) Imidazolone anorectic agents: II. phenyl derivatives. Patent WO 9948888

    Google Scholar 

  • Poindexter GS, Antal I, Giupponi LM et al., Bristol-Myers Squibb Company, USA (2001) NPY antagonists: spiroisoquinolinone derivatives. Patent WO 0113917

    Google Scholar 

  • Poindexter GS, Bruce MA, LeBoulluec KL et al. (2002) Dihydropyridine neuropeptide Y Y(l) receptor antagonists. Bioorg Med Chem Lett 12:379–382

    PubMed  CAS  Google Scholar 

  • Polidori C, Ciccocioppo R, Regoli D et al. (2000) Neuropeptide Y receptor(s) mediating feeding in the rat: characterization with antagonists. Peptides 21:29–35

    PubMed  CAS  Google Scholar 

  • Rabinovich A, Mazurov A, Krokhina G et al. (1997) Discovery of Neuropeptide Y Receptor Antagonists. In: Grundemar L, Bloom S (eds) Neuropeptide Y and drug development. Academic Press, London, San Diego, pp 191–201

    Google Scholar 

  • Ramanjulu J, Aquino C, Palazzo F et al. (2001) Synthesis and structure activity studies of bisheteroaryl guanidines as NPY-Y5 antagonists. 221st ACS National Meeting. San Diego, April 2001 (abstract MEDI-210)

    Google Scholar 

  • Robin-Jagerschmidt C, Sylte I, Bihoreau C et al. (1998) The ligand binding site of NPY at the rat Y1 receptor investigated by site-directed mutagenesis and molecular modeling. Mol Cell Endocrinol 139:187–198

    PubMed  CAS  Google Scholar 

  • Rudolf K, Eberlein W, Wieland HA et al. (1994a) The first highly potent and selective non-peptide NPY Y1 receptor antagonist: BIBP 3226. Eur J Pharm 271:R11–13

    CAS  Google Scholar 

  • Rudolf K, Eberlein W, Engel W et al, (Dr. Karl Thomae GmbH, Germany). (1994b) Preparation of amino acid derivatives as neuropeptide Y antagonists. Patent WO 19940118

    Google Scholar 

  • Rudolf K, Eberlein W, Engel W et al., Boehringer Ingelheim Pharma K.-G., Germany (1999) Preparation of piperazine-containing peptidomimetics for use as NPY antagonists. Patent DE 19816889

    Google Scholar 

  • Rudolf K, Eberlein W, Engel W et al. (1997) BIBP3226, a potent and selective neuropeptide Y Y1-receptor antagonist. Structure-activity studies and localization of the human Y1 receptor binding site. In: Grundemar L, Bloom S (eds) Neuropeptide Y and drug development. Academic Press, London, San Diego, pp 175–190

    Google Scholar 

  • Rüeger H, Schmidlin T, Rigollier P et al., Novartis AG (1997a) Quinazoline-2,4-diazirines as NPY receptor antagonists. Patent WO 9720822

    Google Scholar 

  • Rüeger H, Schmidlin T, Rigollier P et al., Novartis AG (1997b) Quinazoline derivatives useful as antagonists of NPY receptor subtype Y5. Patent WO 9720820

    Google Scholar 

  • Rüeger H, Schmidlin T, Rigollier P et al, Novartis AG (1997c) Heteroaryl Derivatives. Patent WO 9720821

    Google Scholar 

  • Rüeger H, Rigollier P, Yamaguchi Y et al. (2000) Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists. Bioorg Med Chem Lett 10:1175–1179

    Google Scholar 

  • Salaneck E, Holmberg SK, Berglund MM et al. (2000) Chicken neuropeptide Y receptor Y2: structural and pharmacological differences to mammalian Y2(1). FEBS Lett 484:229–234

    PubMed  CAS  Google Scholar 

  • Sato N, Takahashi T, Shibata T et al. (2003) Design and Synthesis of the Potent, Orally Available, Brain-Penetrable Arylpyrazole Class of Neuropeptide Y5 Receptor Antagonists. J Med Chem 46:666–669

    PubMed  CAS  Google Scholar 

  • Satoh Y, Hatori C, Ito H (2002) Novel potent antagonists of human neuropeptide Y-Y5 receptor. Part 4: tetrahydrodiazabenzazulene derivatives. Bioorg Med Chem Lett 12:1009–1011

    PubMed  CAS  Google Scholar 

  • Sautel M, Rudolf K, Wittneben H et al. (1996) Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. Mol Pharmacol 50:285–292

    PubMed  CAS  Google Scholar 

  • Schmidlin T, Rüeger H, Gerspacher M, Novartis A.-G., Switzerland (2001) Preparation of condensed thiazolamines as neuropeptide Y5 antagonists. Patent WO 0164675

    Google Scholar 

  • Serradeil-Le Gal C, Valette G, Rouby P-E et al. (1995) SR120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett 362:192–196

    PubMed  CAS  Google Scholar 

  • Serradeil-Le Gal C (1997) SR 120819A or the first generation of orally active Y1 receptor antagonists. In: Grundemar L, Bloom SR (eds) Neuropeptide Y and drug development. Academic Press, London, San Diego, pp 157–174

    Google Scholar 

  • Shigeri Y, Ishikawa M, Ishihara Y et al. (1998) A potent nonpeptide neuropeptide Y Y1 receptor antagonist, a benzodiazepine derivative. Life Sci 63:PL151–160

    Google Scholar 

  • Silva AP, Cavadas C, Grouzmann E (2002) Neuropeptide Y and its receptors as potential therapeutic drug targets. Clin Chim Acta 326:3–25

    PubMed  CAS  Google Scholar 

  • Sit SY, Huang Y, Antal-Zimanyi I et al. (2002) Novel dihydropyrazine analogues as NPY antagonists. Bioorg Med Chem Lett 12:337–340

    PubMed  CAS  Google Scholar 

  • Smith-White MA, Hardy TA, Brock JA et al. (2001) Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions. Br J Pharmacol 132:861–868

    PubMed  CAS  Google Scholar 

  • Stamford AW, Dugar S, Wu Y et al., Schering Corp., USA (1999) Neuropeptide Y5 receptor antagonists. Patent WO 9964394

    Google Scholar 

  • Stamford AW, Dugar S, Wu Y et al., Schering Corp., USA (2001) Neuropeptide Y5 receptor antagonists. Patent US 6329395

    Google Scholar 

  • Stamford AW, Huang Y, Kelly JM et al, Schering Corp., USA (2002a) Substituted urea neuropeptide Y Y5 receptor antagonists. Patent WO 0222592

    Google Scholar 

  • Stamford AW, Dong Y, McCombie S, Schering Corp., USA (2002b) Heteroaryl urea neuropeptide Y Y5 receptor antagonists. Patent WO 0249648

    Google Scholar 

  • Sylte I, Robin-Jagerschmidt C, Bihoreau C et al. (1998) Molecular modeling of the NPY binding site on the Y1 receptor. J Mol Model 4:221–233

    CAS  Google Scholar 

  • Sylte I, Andrianjara CR, Calvet A et al. (1999) Molecular dynamics of NPY Y1 receptor activation. Bioorg Med Chem 7:2737–2748

    PubMed  CAS  Google Scholar 

  • Tabuchi S, Itani H, Sakata Y et al. (2002) Novel potent antagonists of human neuropeptide Y Y5 receptor. Part 1:2-oxobenzothiazolin-3-acetic acid derivatives. Bioorg Med Chem Lett 12:1171–1175

    PubMed  CAS  Google Scholar 

  • Thurkauf A, Yuan J, Hutchison A et al, Neurogen Corp.; Pfizer Inc. (1999) Preparation of diarylimidazoles as neuropeptide Y receptor ligands. Patent WO 9901128

    Google Scholar 

  • Turnbull AV, Ellershaw L, Masters DJ et al. (2002) Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes 51:2441–2449

    PubMed  CAS  Google Scholar 

  • Walker P, Munoz M, Martinez R et al. (1994) Acidic residues in extracellular loops of the human Y1 neuropeptide Y receptor are essential for ligand binding. J Biol Chem 269:2863–2869

    PubMed  CAS  Google Scholar 

  • Wieland HA, Willim KD, Entzeroth M et al. (1995) Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther 275:143–149

    PubMed  CAS  Google Scholar 

  • Wieland HA, Engel W, Eberlein W et al. (1998) Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol 125:549–555

    PubMed  CAS  Google Scholar 

  • Wright J, Bolton G, Creswell M et al. (1996) 8-Amino-6-(arylsulfonyl)-5-nitroquinolines: novel nonpeptide neuropeptide Y1 receptor antagonists. Bioorg Med Chem Lett 6:1809–1814

    CAS  Google Scholar 

  • Wright J (1997) Design and discovery of neuropeptide Y1 receptor antagonists. Drug Discovery Today 2:19–24

    CAS  Google Scholar 

  • Yokosuka M, Dube MG, Kalra PS et al. (2001) The mPVN mediates blockade of NPY-induced feeding by a Y5 receptor antagonist: a c-FOS analysis. Peptides 22:507–514

    PubMed  CAS  Google Scholar 

  • Youngman MA, McNally JJ, Lovenberg TW et al. (2000) alpha-Substituted N-(sulfonamido) alkyl-beta-aminotetralins: potent and selective neuropeptide Y Y5 receptor antagonists. J Med Chem 43:346–350

    PubMed  CAS  Google Scholar 

  • Zarrinmayeh H, Nunes AM, Ornstein PL et al. (1998) Synthesis and evaluation of a series of novel 2-[(4-chlorophenoxy)methyl]benzimidazoles as selective neuropeptide Y Y1 receptor antagonists. J Med Chem 41:2709–2719

    PubMed  CAS  Google Scholar 

  • Zarrinmayeh H, Zimmerman DM, Cantrell BE et al. (1999) Structure-activity relationship of a series of diaminoalkyl substituted benzimidazole as neuropeptide Y Y1 receptor antagonists. Bioorg Med Chem Lett 9:647–652

    PubMed  CAS  Google Scholar 

  • Zimanyi IA, Poindexter GS (2000) NPY-ergic agents for the treatment of obesity. Drug Dev Res 51:94–111

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pharmacy, University of Regensburg, 93040, Regensburg, Germany

    A. Brennauer, S. Dove & A. Buschauer

Authors
  1. A. Brennauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Dove
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Buschauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Afd. Farmacologie & Farmacotherapie, Academisch Medisch Centrum, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands

    Martin C. Michel

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Brennauer, A., Dove, S., Buschauer, A. (2004). Structure-Activity Relationships of Nonpeptide Neuropeptide Y Receptor Antagonists. In: Michel, M.C. (eds) Neuropeptide Y and Related Peptides. Handbook of Experimental Pharmacology, vol 162. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18764-3_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18764-3_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62282-3

  • Online ISBN: 978-3-642-18764-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation